Cargando…
The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
BACKGROUND: Emicizumab is a nonfactor replacement therapy for hemophilia A (HA) and is a bispecific monoclonal antibody mimicking factor VIII by binding both factors IXa and X. Although it reduces the frequency of bleeding episodes, there is still need for bypassing agents in case of breakthrough bl...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268661/ https://www.ncbi.nlm.nih.gov/pubmed/34263107 http://dx.doi.org/10.1002/rth2.12561 |